- Home
- DHIL vs SIGA Comparison
DHIL vs SIGA Comparison
Compare DHIL & SIGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DHIL | SIGA |
|---|---|---|
| Founded | 1990 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 463.8M | 401.0M |
| IPO Year | 1996 | 2016 |
Fundamental Metrics
Financial Performance| Metric | DHIL | SIGA |
|---|---|---|
| Price | $172.54 | $5.43 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 24.8K | ★ 458.5K |
| Earning Date | 06-01-2026 | 06-15-2026 |
| Dividend Yield | 3.46% | ★ 10.96% |
| EPS Growth | ★ 14.37 | N/A |
| EPS | ★ 17.91 | 0.32 |
| Revenue | ★ $145,201,729.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $132.36 |
| P/E Ratio | ★ $9.67 | $17.11 |
| Revenue Growth | ★ 6.69 | N/A |
| 52 Week Low | $114.11 | $4.95 |
| 52 Week High | $173.70 | $9.62 |
Technical Indicators
Market Signals| Indicator | DHIL | SIGA |
|---|---|---|
| Relative Strength Index (RSI) | 67.10 | 27.79 |
| Support Level | $170.59 | $5.21 |
| Resistance Level | N/A | $6.98 |
| Average True Range (ATR) | 0.81 | 0.26 |
| MACD | -0.08 | -0.13 |
| Stochastic Oscillator | 72.73 | 14.08 |
Price Performance
Historical ComparisonAbout DHIL Diamond Hill Investment Group Inc.
Diamond Hill Investment Group Inc sponsors, markets, and provides investment advisory and related services to various U.S. and foreign clients including mutual funds, separate accounts, and private investment funds. The company's objective is to fulfill a fiduciary duty to clients and secondary objectives to achieve an adequate long-term return for shareholders. The company generates its revenue from Investment advisory and fund administration fees.
About SIGA SIGA Technologies Inc.
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.